Outer surface protein (Osp) C immune pressure during persistent infection with Borrelia burgdorferi was examined in relation to genetic variation of ospC. Mice were infected with clonal B. burgdorferi sensu stricto (s.s.) N40 or B. afzelii PKo and then were hyperimmunized with homologous recombinant OspC or with decorin-binding protein A (DbpA) (controls). After 6 months, B. burgdorferi isolates were subjected to restriction enzyme analysis of the amplified ospC genes and were found to have no differences among 9 B. burgdorferi s.s. N40 and 9 B. afzelii PKo isolates from OspC hyperimmune mice or among 10 B. burgdorferi s.s. N40 and 10 B. afzelii PKo isolates from DbpA hyperimmune mice, compared with input inocula. Comparison of gene sequences among 4 B. burgdorferi s.s. N40 and 9 B. afzelii PKo isolates from OspC-immunized mice revealed no ospC variation from input inocula. Variation in ospC among B. burgdorferi isolates and species during chronic infection is not likely to be an important mechanism for immune evasion.
malian hosts. OspC is a highly immunogenic antigen that elicits an early antibody response during infection [3] .
The variable nature of OspC is reflected in its conditional ability to induce protective immunity. OspC immunization elicits protective immunity against challenge with homologous B. burgdorferi strains, but challenge of OspC-immunized mice with heterologous B. burgdorferi strains does not confer protection. In contrast, mice immunized with OspA can be protected against challenge with heterologous isolates and different B. burgdorferi s.l. species [4] . Furthermore, homologous OspC immunization may not be effective with some strains of B. burgdorferi (e.g., B. burgdorferi s.s. N40). Laboratory mice immunized with antisera to recombinant (r) OspC-PKo resisted challenge with B. afzelii strain PKo, but mice immunized with antisera to rOspC-N40 were fully susceptible to challenge with B. burgdorferi s.s. N40 [5] . Of note, there is one report [6] that passive immunization with OspC antiserum of mice with severe combined immunodeficiency can therapeutically eliminate ongoing infection with homologous B. burgdorferi s.s. ZS7.
To test the hypothesis that OspC immunity may place immune selection pressure upon B. burgdorferi during persistent infection, appropriate B. burgdorferi strains must be examined and clonal populations of infecting spirochetes must be used to obviate OspC variation in the inocula. Therefore, mice were infected with clonal populations of either B. burgdorferi s.s. N40 or B. afzelii PKo (whose OspCs do not, or do, invoke protective immunity, respectively). Mice with established infections were hyperimmunized with the respective rOspC (N40 or PKo) or with an irrelevant but protection-inducing recombinant protein of similar size (decorin-binding protein A [DbpA]-N40). After 6 months of persistent infection under in-tense OspC hyperimmune pressure, spirochetes were examined for evidence of gene variation.
Materials and Methods

Mice.
Random-sex 3-week-old C3H/HeN mice were purchased (animal production program; Frederick Cancer Research Center, Frederick, MD). At 4 weeks of age, mice were inoculated intradermally on the dorsal thoracic midline with 10 4 B. burgdorferi s.s. N40 or B. afzelii PKo in 0.1 mL of culture medium. Necropsies were done 6 months after infection.
Borreliae. B. burgdorferi s.s. N40 and B. afzelii PKo were grown in BSK II medium, cloned by 3ϫ limiting dilution, and enumerated as described [5] . At necropsy, tissues (blood, spleen, urinary bladder, inoculation site, and ear) were collected aseptically and cultured in BSK II medium.
Recombinant proteins. rOspC-N40 and rOspC-PKo were constructed and generated as glutathione transferase fusion proteins with primers corresponding to bp 58-69 and 616-627 of the B. burgdorferi s.s. N40 and B. afzelii ospC genes, respectively [5] . As a control antigen, we selected DbpA-N40, a lipoprotein that elicits protective immunity against B. burgdorferi s.s. N40. DbpA is similar in size (∼22 kDa) to OspC but has no sequence similarity to OspC [7] . The resultant recombinant proteins were cleaved from glutathione transferase with thrombin and were used to hyperimmunize mice 4 weeks after infection. Mice were immunized subcutaneously with 20 mg of recombinant protein in complete Freund's adjuvant and boosted twice with 10 mg of protein in incomplete Freund's adjuvant at 2-week intervals, followed by a final boost 2 months later (4 months after infection).
Immunoblots. B. burgdorferi lysates, rOspC-N40 or rOspCPKo, were transferred from a 15% acrylamide resolving gel and 3% stacking gel to nitrocellulose paper. Infection of mice was verified prior to OspC immunization by testing serum reactivity with B. burgdorferi s.s. N40 or B. afzelii PKo lysates. Reactivity with 41-kDa (flagellin), 39-kDa (Bmp), and 22-kDa proteins was considered indicative of active infection. Infection was ultimately confirmed in all mice by culture at necropsy. Serum reactivity of hyperimmunized mice to rOspC-N40 or rOspC-PKo was verified to exceed serum dilutions of 11 : 100,000 against the recombinant antigen.
Evaluation of ospC genes. The ospC gene was amplified from each isolate by polymerase chain reaction (PCR) with forward primer 5 -CGCGGATCCTGCAAAGAAAAATTGTTGGAC-3 and reverse primer 5 -CGCGGATCCCCAGTTACTTTTTTA-AAACAA-3 , which were complementary to conserved DNA flanking regions of both the ospC-N40 and ospC-PKo genes, ∼30 bp upstream and downstream of the genes, respectively [8] . The ospC amplicons were subjected to restriction fragment length polymorphism (RFLP) analysis with restriction enzymes DdeI, DpnII, and DraI (New England BioLabs, Beverly, MA). Digested products were separated on a 1% agarose gel. PCR-amplified ospC DNA from each isolate was also cloned into pCRII vector (Invitrogen, Carlsbad, CA), and both forward and reverse strands were sequenced at the W. M. Keck Foundation Biotechnology Resource Laboratory, Yale School of Medicine (New Haven, CT). DNA sequence was analyzed by use of the MacVector program (Kodak, New Haven).
Results
Previous studies have shown that OspC-N40 immunization does not protect against cloned B. burgdorferi s.s. N40 challenge, but OspC-PKo immunization protects against cloned B. afzelii PKo challenge [5] . Thus, we could not directly verify whether immunizing doses of OspC-N40 were given. To verify that immunizing doses of OspC-PKo were given, a pilot experiment was performed with antisera developed in C3H mice immunized according to the same regimen and with the same rOspC-PKo used in the subsequent experiment. Groups of 4 mice were passively immunized with 500 mL of 1 : 10 diluted OspC-PKo antiserum at Ϫ18 h relative to challenge, days 4, 8, and 12 relative to challenge, or days 8 and 12 relative to challenge with 10 4 B. afzelii PKo. A control group of mice received normal mouse serum at Ϫ18 h and 4, 8, and 12 days relative to challenge. Culture of urinary bladder, inoculation site, and ear 2 weeks after challenge revealed that no mice (0/4) immunized with OspC-PKo antiserum at Ϫ18 h became infected (4/4 protected), whereas all 8 mice immunized with OspC-PKo on day 4 and beyond were infected. All 4 mice that received normal mouse serum were infected. This experiment verified that our OspC immunization regimen (OspC-PKo) elicited protective antibody with proven effect. Thus, we presumed that OspC-PKo hyperimmunization during established infection would create an appropriately strong immune pressure to test our hypothesis and that a similar regimen of OspC-N40 hyperimmunization would serve as a control group for a B. burgdorferi strain that is not susceptible to OspC protective immunity.
We next inoculated 2 groups of 20 mice each with B. burgdorferi s.s. N40 or B. afzelii PKo. Four weeks after inoculation, half the mice in each group were hyperimmunized with the homologous rOspC; the other half of each group were hyperimmunized with DbpA-N40 (control antigen). At 6 months after inoculation, necropsies were done, and multiple tissues were cultured to verify infection and to obtain isolates for ospC gene evaluation. All 20 mice were culture positive. Histology of joints and hearts was not done, because chronically infected mice have minimal or no disease [5] 
Discussion
There is significant OspC heterogeneity among B. burgdorferi species and isolates at both the antigenic and genetic levels [2, 9] . The ospC genes of 22 B. burgdorferi s.s., B. garinii, and B. afzelii isolates from Lyme disease patients have been cloned and sequenced and compared with 16S RNA genes as an independent phylogenetic marker, and ospC sequences revealed both conserved and variable regions. Comparison of the conserved region of ospC among different isolates indicated that ospC and 16S RNA gene sequences coevolved at equal rates; however, comparison of the variable region of ospC revealed that ospC diversity evolved at a greater rate than did diversity in other B. burgdorferi genes. Furthermore, the variable regions of ospC most often coincided with areas of high antigenicity index, suggesting that host immune pressure may play a role in ospC diversity [10] .
Immune evasion through antigenic variation by orderly gene rearrangement is well established with B. hermsii, a relapsing fever agent that is related to B. burgdorferi. B. hermsii evades immune clearance by a complex mechanism in which there are functional rearrangements of у26 related genes to create novel surface-exposed lipoproteins, termed variable major proteins (Vmps) [11] . There is evidence that B. burgdorferi OspC shares considerable sequence similarity and antigenic cross-reactivity with Vmp33 of B. hermsii, suggesting evolutionary relatedness and common function. Vmp33 of B. hermsii has more amino acid similarity to OspC than to other Vmps of B. hermsii, and OspC has more similarity to Vmp33 than to other B. burgdorferi Osps (A, B, and D) [12] . Although not related to OspC, B. burgdorferi possesses a vmp-like sequence gene complex that serves a purpose similar to that of the vmp complex in B. hermsii [11, 13] .
Thus, it is attractive to speculate that ospC represents a variable gene for the purpose of immune evasion during persistent infection. Analysis of B. burgdorferi isolated from persistently infected mice, following original injection with a clonal inoculant of B. burgdorferi s.s. N40, revealed virtually no ospC gene variation [14] . However, the N40 strain of B. burgdorferi may be an inappropriate candidate to examine immune selection pressure, because studies have shown that active or passive immunization against rOspC-N40 does not protect against challenge with the B. burgdorferi s.s. N40 [5] . Although mice infected with B. burgdorferi s.s. N40 readily and rapidly seroconvert to OspC [3, 7] , B. burgdorferi s.s. N40 may represent an anomaly, particularly since we and others have shown that OspC immunization is protective against other homologous strains of B. burgdorferi [4, 5] . We therefore selected B. afzelii PKo as a B. burgdorferi s.l. strain that is susceptible to protective immunity induced by immunization with rOspC-PKo [5] and compared the results with B. burgdorferi s.s. N40 as a negative control.
By use of hyperimmune serum from mice that received an immunization regimen and recombinant protein equivalent to the experimental regimen utilized to hyperimmunize persistently infected mice, we validated that OspC-PKo antiserum was protective. Thus, it was safe to assume that hyperimmunization of actively infected mice would result in even higher immune pressure. Since OspC-N40 is not protective against B. burgdorferi s.s. N40 [5] , we could only assume that an immunization regimen similar to that used for OspC-PKo would yield an equally strong immune pressure on B. burgdorferi s.s. N40 during active infection, but potentially without the vulnerability of B. burgdorferi s.s. N40. As an additional control, we immunized actively infected mice with rDbpA-N40, a lipoprotein of similar size to OspC that we have shown to be protective against B. burgdorferi s.s. N40 challenge, but not after infection is established [7] .
In mice infected with OspC-susceptible B. afzelii PKo and OspC-resistant B. burgdorferi s.s. N40, we found virtually no evidence for gene variation under intense immune selection pressure and persistent infection with either B. burgdorferi s.l. strain and no ospC variation among B. afzelii PKo or B. burgdorferi s.s. N40 isolates from mice immunized with DbpA-N40. Thus, these results extend previous findings of no ospC gene variation in mice persistently infected with B. burgdorferi s.s. N40 [14] . These results support an alternate hypothesis for ospC gene variation, which has been proposed to be caused by lateral transfer of genetic material between spirochetes rather than by exchange of genetic material within a single organism or clonal population [15] . Lateral transfer requires mixed infection with nonclonal populations of spirochetes within the vector or the host, both of which are well documented with B. burgdorferi.
